Parotis Bezi Yerleşimli Malign Melanomlar

Yıl 2024, Cilt: 6 Sayı: 2, 193 - 199, 30.06.2024

Yakup Duzkopru Ünsal Han Abdülkadir Koçanoğlu Özlem Doğan Hayriye Şahinli Gökşen İnanç İmamoğlu

https://doi.org/10.52827/hititmedj.1429875

Öz

Amaç: Parotis bezi içerisinde yer alan malign melanom, nadir bir klinik sunumu temsil eder ve bu hastaların prognozu, diğer malign melanom türleriyle karşılaştırıldığında yeterince anlaşılamamıştır. Bu çalışma, kliniğimizde takip edilen parotis bezi içerisinde bulunan malign melanom vakalarını değerlendirmeyi amaçlamaktadır.
Gereç ve Yöntem: Parotis bezi içinde veya komşuluğunda lokalize melanom tanısı alan 18 yaş ve üstü 5 hastanın kayıtları geriye dönük olarak incelendi. Hastaların yaş ve cinsiyet gibi demografik bilgileri, tıbbi geçmişleri, başvuru semptomları, tedavi yöntemleri ve sonuçları gibi ilgili klinik bilgiler gözden geçirildi. Hastaların genel sağkalımları incelendi.
Bulgular: Çalışmaya dahil edilen hastaların hiçbirinde primer parotis bezi melanomu yoktu. Dört hastada primer lezyonlar baş ve boyun bölgesinden kaynaklanan kutanöz melanomlardı, bir hastada ise primer lezyon gözde yer alan üveal melanomdu. Çalışmaya alınan 3 hasta ölmüşken 2 hastanın takibi devam ediyordu.
Sonuç: Parotis bezinde lokalize olan primer melanomlar son derece nadir olup, parotis bezi melanomu ile karşılaşıldığında kapsamlı bir tıbbi öykü ve dikkatli bir fizik muayene ile primer lezyonun ağırlıklı olarak baş boyun bölgesinde yerleşen kutanöz melanom olduğu sıklıkla ortaya konulabilir. Ancak nadir de olsa parotis bezinde primeri bilinmeyen veya primer intranodal melanom vakaları olabileceği akılda tutulmalıdır.

Anahtar Kelimeler

Baş ve boyun kanseri, melanom, primeri bilinmeyen neoplaziler, parotis tümörleri

Malignant Melanoma Localized to the Parotid Gland

Öz

Objective: Malignant melanoma situated in the parotid gland represents a rare clinical presentation, and the prognosis of these patients remains inadequately understood in comparison to other forms of malignant melanoma. This study aims to evaluate cases of parotid gland-located malignant melanoma under follow-up in our clinic.
Material and Method: Records of five patients aged 18 and above, diagnosed with melanoma localized within or adjacent to the parotid gland, were retrospectively reviewed. Relevant clinical information such as patients’ demographic data including age and gender, medical histories, presenting symptoms, treatment modalities, and outcomes were evaluated. The overall survival of the patients was examined.
Results: None of the patients included in the study had primary parotid gland melanoma. Among all patients, 4 patients had primary lesions that were cutaneous melanomas originating from the head and neck region, while in one patient, the primary lesion was uveal melanoma of the eye. While 3 patients included in the study had died, 2 patients were still being followed up.
Conclusion: Primary melanomas localized to the parotid gland are extremely rare, and when encountered, a thorough medical history and careful physical examination can often reveal that the primary lesion is cutaneous melanoma, predominantly located in the head and neck region. It should be kept in mind that although rare, there may be primary intranodal melanoma cases whose primary is unknown or cannot be found in the parotid gland.

Anahtar Kelimeler

Head and neck cancer, melanoma, neoplasms, unknown primary, parotid neoplasms

Etik Beyan

The ethics committee approval of the study was given by the local ethics committee. (number:2023-783, date:10.01.2024)

Kaynakça

• Badlani J, Gupta R, Smith J, et al. Metastases to the parotid gland - A review of the clinicopathological evolution, molecular mechanisms and management. Surg Oncol 2018;27(1):44-53.
• Mesa M, Quesada JL, Pinas J. Metastasis of amelanotic melanoma of unknown origin in the parotid gland. Br J Oral Maxillofac Surg 2009;47(7):569-571.
• Ahadi M, Rakhshan A, Mousavi SR, Saebnoori H. Malignant melanoma of parotid glands from a neglected lesion: A case report. Clin Case Rep 2021;9(10):e04941.
• Barbieri M, Gentile R, Cordone MP, Mora R, Mora F. Primitive malignant melanoma of the parotid gland. ORL J Otorhinolaryngol Relat Spec 2002;64(4):297-299.
• O’Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS. Incidence of cervical node involvement in metastatic cutaneous malignancy involving the parotid gland. Head Neck 2001;23(9):744-748.
• Woodwards RT, Shepherd NA, Hensher R. Malignant melanoma of the parotid gland: a case report and literature review. Br J Oral Maxillofac Surg 1993;31(5):313-315.
• Takeda Y. Melanocytes in the human parotid gland. Pathol Int 1997;47(8):581-583.
• Prayson RA, Sebek BA. Parotid gland malignant melanomas. Arch Pathol Lab Med 2000;124(12):1780-1784.
• Kılıçkaya MM, Aynali G, Ceyhan AM, Çiriş M. Metastatic Malignant Melanoma of Parotid Gland with a Regressed Primary Tumor. Case Reports in Otolaryngology 2016;2016:1-4.
• Franzen AM, Coordes A, Franzen CK, Guenzel T. Are Multiple Tumors of the Parotid Gland Uncommon or Underestimated? Anticancer Res 2017;37(9):5263-5267.
• Chaouki A, Berrada O, Najib Z, et al. Primary malignant melanoma of the parotid gland: A case report and review of the literature. Ann Med Surg (Lond) 2020;60:660-663.
• Saqi A, McGrath CM, Skovronsky D, Yu GH. Cytomorphologic features of fine-needle aspiration of metastatic and recurrent melanoma. Diagn Cytopathol 2002;27(5):286-290.
• Wang BY, Lawson W, Robinson RA, Perez-Ordonez B, Brandwein M. Malignant Melanomas of the Parotid. Archives of Otolaryngology–Head & Neck Surgery 1999;125(6):635.
• Park YM, Koh YW. Current Issues in Treatment of Parotid Gland Cancer and Advanced Surgical Technique of Robotic Parotidectomy. Curr Oncol Rep 2022;24(2):203-208.
• Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018;19(10):1315-1327.
• Larkin J, Ascierto PA, Dreno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371(20):1867-1876.
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372(1):30-39.
• Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015;373(13):1270-1271.
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16(8):908-918.